Drug intelligence / Profile preview

2B11

Development stage: Unknown
Lead developer: China National Biotec
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

2B11 is a human monoclonal antibody developed by China National Biotec Group. It targets the G protein of respiratory syncytial virus (RSV) and has demonstrated both prophylactic and therapeutic efficacy in preclinical models, reducing viral load, leukocyte infiltration, and inflammatory cytokine expression. The drug is being investigated for use in infectious diseases, particularly COVID-19 and other respiratory diseases. Its mechanism involves neutralizing RSV by binding to the G protein, thereby inhibiting viral entry and modulating immune responses[1].

Targets

RSV G (Respiratory syncytial virus attachment glycoprotein)

Beyond the preview

Go deeper on 2B11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2B11.

Explore the full profile